Skip to main content
Equibles
BCRX logo

BCRX · Biocryst Pharmaceuticals Inc · Earnings Call Transcripts & Audio

Track BCRX — free

Use BCRX with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research BCRX.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$8.39 +0.12 (+1.49%) At close · Sep 30
Russell 2000 member Rebalance outlook locked
Market Cap
$2.11B
Shares
255.54M
Volume · Sep 30 13.1M Avg daily vol (3M) 4.11M

Biocryst Pharmaceuticals Inc Earnings Call Transcripts

Quarterly earnings calls for Biocryst Pharmaceuticals Inc (BCRX), with available speaker-labelled transcripts, captured audio replays, call highlights, 8-K earnings releases and periodic filings. Investor days and conferences appear here too.

Pull transcripts and briefs through the earnings call transcript API or MCP →

Revenue & result across quarters

Revenue Net income YoY up YoY down artefacts
▲85% $75.83M −$42.52M '22 Q3 22-11-01 ▲68.7% $79.55M −$71.54M '22 Q4 23-01-09 ▲37.8% $68.78M −$53.33M '23 Q1 23-05-03 ▲25.9% $82.49M −$75.33M '23 Q2 23-08-03 ▲14.4% $86.74M −$36.15M '23 Q3 23-11-02 ▲17.4% $93.40M −$61.73M '23 Q4 24-02-26 ▲34.9% $92.76M −$35.38M '24 Q1 24-05-06 ▲32.5% $109.33M −$12.67M '24 Q2 24-08-05 ▲35% $117.08M −$14.03M '24 Q3 24-11-04 ▲40.8% $131.53M −$26.80M '24 Q4 25-02-24 ▲56.9% $145.53M $32,000 '25 Q1 25-05-05 ▲49.4% $163.35M $5.08M '25 Q2 25-08-04 ▲36.1% $159.40M $12.90M '25 Q3 25-10-14 ▲209.1% $406.56M $245.84M '25 Q4 26-02-26 ▲7.5% $156.41M −$721.81M '26 Q1 26-05-06 LATEST ▲33.6% $218.25M $78.39M '26 Q2 26-08-05
Conference
Investor event
2026-09-15
Biocryst Pharmaceuticals Inc (BCRX) September 2026 Conference Transcript
No reported result — non-financial event
Audio Transcript Slides
Earnings call
FY26 · Q2
2026-08-05
Biocryst Pharmaceuticals Inc (BCRX) Q2 2026 Earnings Call Transcript
Confident tone Pediatric launch (Orladeyo pellets) Demand momentum and new prescribers Patient retention / stickiness
Revenue
$218.25M
▲ 33.6% YoY
Diluted EPS
$0.30
▲ 1400% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Conference
Investor event
2026-06-03
Biocryst Pharmaceuticals Inc (BCRX) June 2026 Conference Transcript
No reported result — non-financial event
Audio Transcript Slides
Earnings call
FY26 · Q1
2026-05-06
Biocryst Pharmaceuticals Inc (BCRX) Q1 2026 Earnings Call Transcript
Confident tone ORLADEYO commercial performance Navenibart / ALPHA-ORBIT Phase 3 Pediatric pellet launch and manufacturing delay
Revenue
$156.41M
▲ 7.5% YoY
Diluted EPS
$-2.98
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q4
2026-02-26
Biocryst Pharmaceuticals Inc (BCRX) Q4 2025 Earnings Call Transcript
Confident tone HAE market structure and competition ORLADEYO commercial performance and growth Navenibart Phase III program
Revenue
$406.56M*
▲ 209.1% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY25 · Q3
2025-10-14
Biocryst Pharmaceuticals Inc (BCRX) Q3 2025 Earnings Call Transcript
Confident tone ORLADEYO revenue growth and guidance raise BCX17725 for Netherton syndrome Astria acquisition and navenibart asset
Revenue
$159.40M
▲ 36.1% YoY
Diluted EPS
$0.06
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q2
2025-08-04
Biocryst Pharmaceuticals Inc (BCRX) Q2 2025 Earnings Call Transcript
Confident tone ORLADEYO commercial momentum CEO succession and BioCryst 2.0 / BD strategy Pipeline programs (Netherton, DME)
Revenue
$163.35M
▲ 49.4% YoY
Diluted EPS
$0.02
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q1
2025-05-05
Biocryst Pharmaceuticals Inc (BCRX) Q1 2025 Earnings Call Transcript
Confident tone ORLADEYO commercial performance Profitability and financial strength Pipeline progress (BCX17725, avoralstat)
Revenue
$145.53M
▲ 56.9% YoY
Diluted EPS
$0.00
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q4
2025-02-24
Biocryst Pharmaceuticals Inc (BCRX) Q4 2024 Earnings Call Transcript
Confident tone Pediatric Orladeo label expansion BCX1775 for Netherton syndrome Medicare / Inflation Reduction Act impact
Revenue
$131.53M*
▲ 40.8% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY24 · Q3
2024-11-04
Biocryst Pharmaceuticals Inc (BCRX) Q3 2024 Earnings Call Transcript
Confident tone BCX17725 for Netherton Syndrome Pipeline Pediatric Label Expansion and ORLADEYO Granules Medicare and Non-Commercial Access Risks
Revenue
$117.08M
▲ 35% YoY
Diluted EPS
$-0.07
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q2
2024-08-05
Biocryst Pharmaceuticals Inc (BCRX) Q2 2024 Earnings Call Transcript
Confident tone ORLADEYO Commercial Performance 2024 Revenue Guidance Raise Long-Term $1B Peak Sales Opportunity
Revenue
$109.33M
▲ 32.5% YoY
Diluted EPS
$-0.06
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q1
2024-05-06
Biocryst Pharmaceuticals Inc (BCRX) Q1 2024 Earnings Call Transcript
Confident tone ORLADEYO commercial performance Pipeline advancement Pediatric program and filing
Revenue
$92.76M
▲ 34.9% YoY
Diluted EPS
$-0.17
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q4
2024-02-26
Biocryst Pharmaceuticals Inc (BCRX) Q4 2023 Earnings Call Transcript
Confident tone ORLADEYO Commercial Performance Real-World Evidence and Clinical Data HAE Market Dynamics
Revenue
$93.40M*
▲ 17.4% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY23 · Q3
2023-11-02
Biocryst Pharmaceuticals Inc (BCRX) Q3 2023 Earnings Call Transcript
Revenue
$86.74M
▲ 14.4% YoY
Diluted EPS
$-0.19
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q2
2023-08-03
Biocryst Pharmaceuticals Inc (BCRX) Q2 2023 Earnings Call Transcript
Revenue
$82.49M
▲ 25.9% YoY
Diluted EPS
$-0.40
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q1
2023-05-03
Biocryst Pharmaceuticals Inc (BCRX) Q1 2023 Earnings Call Transcript
Revenue
$68.78M
▲ 37.8% YoY
Diluted EPS
$-0.28
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q4
2023-01-09
Biocryst Pharmaceuticals Inc (BCRX) Q4 2022 Earnings Call Transcript
Revenue
$79.55M*
▲ 68.7% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY22 · Q3
2022-11-01
Biocryst Pharmaceuticals Inc (BCRX) Q3 2022 Earnings Call Transcript
Revenue
$75.83M
▲ 85% YoY
Diluted EPS
$-0.23
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q2
2022-08-04
Biocryst Pharmaceuticals Inc (BCRX) Q2 2022 Earnings Call Transcript
Revenue
$65.53M
▲ 31.2% YoY
Diluted EPS
$-0.32
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q1
2022-05-05
Biocryst Pharmaceuticals Inc (BCRX) Q1 2022 Earnings Call Transcript
Revenue
$49.92M
▲ 161.9% YoY
Diluted EPS
$-0.40
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY21 · Q4
2022-01-10
Biocryst Pharmaceuticals Inc (BCRX) Q4 2021 Earnings Call Transcript
Revenue
$47.16M*
▲ 1074.3% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY21 · Q3
2021-11-03
Biocryst Pharmaceuticals Inc (BCRX) Q3 2021 Earnings Call Transcript
Revenue
$40.99M
▲ 571.8% YoY
Diluted EPS
$-0.33
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY21 · Q2
2021-08-05
Biocryst Pharmaceuticals Inc (BCRX) Q2 2021 Earnings Call Transcript
Revenue
$49.96M
▲ 1640.1% YoY
Diluted EPS
$-0.24
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY21 · Q1
2021-05-06
Biocryst Pharmaceuticals Inc (BCRX) Q1 2021 Earnings Call Transcript
Revenue
$19.06M
▲ 295.2% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY20 · Q4
2021-02-25
Biocryst Pharmaceuticals Inc (BCRX) Q4 2020 Earnings Call Transcript
Revenue
$4.02M
▼ 89.9% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY20 · Q3
2020-11-05
Biocryst Pharmaceuticals Inc (BCRX) Q3 2020 Earnings Call Transcript
Revenue
$6.10M
▲ 243.8% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY20 · Q2
2020-08-06
Biocryst Pharmaceuticals Inc (BCRX) Q2 2020 Earnings Call Transcript
Revenue
$2.87M
▲ 98.3% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY20 · Q1
2020-05-06
Biocryst Pharmaceuticals Inc (BCRX) Q1 2020 Earnings Call Transcript
Revenue
$4.82M
▼ 18.1% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY19 · Q4
2020-03-05
Biocryst Pharmaceuticals Inc (BCRX) Q4 2019 Earnings Call
Revenue
$39.73M
▲ 1355.7% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Showing 1–29 of 29 earnings calls
Key facts CIK 882796 CUSIP 09058V103 13F (30d) 10 filings 9 filers Visit website Investor relations